AdenomyosisSymptoms, Doctors, Treatments, Advances & More
Learn About Adenomyosis
Condition 101 content is not available at this time, but we are continually updating the site. Please check back.
However, there may be experts who have treated this or similar conditions in our Find a Doctor section and research may be available in our Latest Advances section.
Jacques Donnez practices practicing medicine in Brussels, Belgium. Mr. Donnez is rated as an Elite expert by MediFind in the treatment of Adenomyosis. He is also highly rated in 7 other conditions, according to our data. His clinical expertise encompasses Uterine Fibroids, Menorrhagia, Infertility, Hysterectomy, and Hormone Replacement Therapy (HRT).
Mathilde Bourdon practices practicing medicine in Paris, France. Ms. Bourdon is rated as an Elite expert by MediFind in the treatment of Adenomyosis. She is also highly rated in 5 other conditions, according to our data. Her clinical expertise encompasses Adenomyosis, Endometriosis, Infertility, Ovarian Hyperstimulation Syndrome, and Hormone Replacement Therapy (HRT).
Pietro Santulli practices practicing medicine in Paris, France. Mr. Santulli is rated as an Elite expert by MediFind in the treatment of Adenomyosis. He is also highly rated in 5 other conditions, according to our data. His clinical expertise encompasses Endometriosis, Adenomyosis, Infertility, Hormone Replacement Therapy (HRT), and Oophorectomy.
Summary: Our study aims to assess the prevalence of adenomyosis and endometriosis in patients consulting for elective fertility preservation through the diagnosis of these pathologies by transvaginal pelvic ultrasound. Imaging data will be compared with clinical data (patient characteristics, clinical symptoms) as well as the assessment of anxiety, depression, and quality of life collected from the women.
Summary: ELECTRE is a single-center, randomized, prospective, longitudinal, controlled, two-arm, single-blind study lasting 4 weeks (P1 investigation phase) after a 4-week run-in period. The study is followed by a 4-week extension phase (P2) in which all participants will be treated with active TENS. Randomization will be balanced according to a 1:1 ratio.